公开(公告)号：US11929151B2

公开(公告)日：2024-03-12

申请号：US17158940

申请日：2021-01-26

Applicant: Immunocore Limited ,  Adaptimmune Limited

Inventor： Brian John Cameron ,  Annelise Brigitte Vuidepot ,  Bent Karsten Jakobsen

IPC: G01N33/50 ,  G01N33/68 ,  G16B35/00 ,  G16B35/20 ,  G16C20/60

CPC classification number: G16B35/20 ,  G01N33/505 ,  G01N33/6866 ,  G01N33/6878 ,  G16B35/00 ,  G16C20/60 ,  G01N2333/57 ,  G01N2333/70539 ,  G01N2500/04

Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.

公开(公告)号：US20240055076A1

公开(公告)日：2024-02-15

申请号：US18266387

申请日：2021-12-09

Applicant: Cambridge Enterprise Limited ,  International Centre for Genetic Engineering and Biotechnology

Inventor： Sudhakaran PRABAKARAN

IPC: G16B35/00 ,  G16B20/20 ,  C12N15/10

CPC classification number: G16B35/00 ,  G16B20/20 ,  C12N15/1089

Abstract: The present application features methods of treating a disease associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant encodes either the gain or loss of a stop codon.

公开(公告)号：US11901042B2

公开(公告)日：2024-02-13

申请号：US15976956

申请日：2018-05-11

Applicant: Thuraiayah Vinayagamoorthy

Inventor： Thuraiayah Vinayagamoorthy

IPC: G16B20/20 ,  C12Q1/6886 ,  G16B5/00 ,  G16B10/00 ,  G16B15/00 ,  G16B20/00 ,  G16B25/00 ,  G16B30/00 ,  G16B35/00 ,  G16B40/00 ,  G16B45/00 ,  G16B50/00

CPC classification number: G16B20/20 ,  C12Q1/6886 ,  G16B5/00 ,  G16B10/00 ,  G16B15/00 ,  G16B20/00 ,  G16B25/00 ,  G16B30/00 ,  G16B35/00 ,  G16B40/00 ,  G16B45/00 ,  G16B50/00 ,  C12Q2600/154 ,  C12Q2600/156

Abstract: Somatic mutations are associated with cancer progression and treatment using targeted therapies. Somatic mutations are not inherited and could be present at low concentrations in biopsy samples. Hence, there is a need for more sensitive assays to detect these changes in the presence of heterogeneous cell populations. The efficacy of such detection is determined by two factors; the ability to detect a minimum number of copies of the target mutation in the sample (Lower limit of detection), and the ratio of target mutation to that of wild-type in the sample (Tumor content). A new algorithm Detection Index (DI) is formulated to evaluate the efficacy of detection for a molecular testing method.

公开(公告)号：US20240047005A1

公开(公告)日：2024-02-08

申请号：US18221440

申请日：2023-07-13

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Takahiro NAKAMURA ,  Yusuke Yagi ,  Keiko Kobayashi

IPC: G16B15/00 ,  G16B30/00 ,  G16B35/00 ,  G16C20/60 ,  C07K14/415 ,  C12N15/82 ,  G16B20/50 ,  G16B20/30 ,  G16B30/10 ,  C12Q1/68 ,  G01N33/53

CPC classification number: G16B15/00 ,  G16B30/00 ,  G16B35/00 ,  G16C20/60 ,  C07K14/415 ,  C12N15/8216 ,  C12N15/8289 ,  G16B20/50 ,  G16B20/30 ,  G16B30/10 ,  C12Q1/68 ,  G01N33/5308 ,  C12N15/8287 ,  G16B20/00

Abstract: A method for designing a protein capable of binding in an RNA base selective manner or RNA base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of PPR motifs (preferably 2 to 14 PPR motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein Helix A is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, A1 to A12 independently represent an amino acid; X does not exist, or is a moiety of 1- to 9-amino acid length; Helix B is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and L is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (−1), “ii” (−2), and so on from the C-terminus side, provided that Liii to Lvii may not exist), and combination of three amino acids A1, A4 and Lii, or combination of two amino acids A4, and Lii is a combination corresponding to a target RNA base or base sequence.

公开(公告)号：US11810650B2

公开(公告)日：2023-11-07

申请号：US16592070

申请日：2019-10-03

Applicant: Gusto Global, LLC

Inventor： Daniel van der Lelie ,  Safiyh Taghavi

IPC: G06G7/48 ,  G16B5/00 ,  A61K35/741 ,  A61K35/742 ,  G16B35/20 ,  G16B35/00 ,  G16B99/00

CPC classification number: G16B5/00 ,  A61K35/741 ,  A61K35/742 ,  G16B35/00 ,  G16B35/20 ,  G16B99/00

Abstract: Methods are provided for the rational design of stable communities of microbes for benefiting the health of a host organism, including human and/or animal health. The methods describe design of microbial consortia based on providing and/or complementing key functionalities lacking or underrepresented in the microbiome of an organism having a disorder or disease as compared to healthy subjects. The consortia are designed to possess metabolic interdependencies for improved engrafting, stability and performance of the consortium. Compositions that include the designed microbial consortia are provided for treatment of disorders/diseases involving chronic inflammation, infection, and the combination of chronic inflammation and infection including inflammatory bowel disease and related disorders. The compositions are also broadly applicable for the treatment of neurological, metabolic and oncology-related conditions.

公开(公告)号：US20230274798A1

公开(公告)日：2023-08-31

申请号：US18072417

申请日：2022-11-30

Applicant: GGF Global Genomics Pty Limited

Inventor： Christopher Charles Hagan

IPC: G16B45/00 ,  G16B30/00 ,  G16B35/00

CPC classification number: G16B45/00 ,  G16B30/00 ,  G16B35/00

Abstract: The invention relates to a sequence analysis method or sequence generation method for analysing or generating sequences of encoding elements of a particular DNA, RNA, or macromolecule sequence. The invention also relates to a manual, automated or computer implemented method of recognizing, analysing, probing, testing, processing, sequencing and sensing DNA or other macromolecular sequences.

公开(公告)号：US11742056B2

公开(公告)日：2023-08-29

申请号：US17195449

申请日：2021-03-08

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Takahiro Nakamura ,  Yusuke Yagi ,  Keiko Kobayashi

IPC: G16B15/00 ,  G16B30/00 ,  G16B35/00 ,  G16C20/60 ,  C07K14/415 ,  C12N15/82 ,  G16B20/50 ,  G16B20/30 ,  G16B30/10 ,  C12Q1/68 ,  G01N33/53 ,  G16B20/00

CPC classification number: G16B15/00 ,  C07K14/415 ,  C12N15/8216 ,  C12N15/8287 ,  C12N15/8289 ,  C12Q1/68 ,  G01N33/5308 ,  G16B20/30 ,  G16B20/50 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16C20/60 ,  C07K2319/85 ,  C12Q2522/101 ,  G16B20/00

Abstract: A method for designing a protein capable of binding in an RNA base selective manner or RNA base sequence specific manner is provided. The protein of the present invention is a protein containing one or more of PPR motifs (preferably 2 to 14 PPR motifs) each consisting of a polypeptide of 30- to 38-amino acid length represented by the formula 1 (wherein Helix A is a moiety of 12-amino acid length capable of forming an α-helix structure, and is represented by the formula 2, wherein, in the formula 2, A1 to A12 independently represent an amino acid; X does not exist, or is a moiety of 1- to 9-amino acid length; Helix B is a moiety of 11- to 13-amino acid length capable of forming an α-helix structure; and L is a moiety of 2- to 7-amino acid length represented by the formula 3, wherein, in the formula 3, the amino acids are numbered “i” (−1), “ii” (−2), and so on from the C-terminus side, provided that Liii to Lvii may not exist), and combination of three amino acids A1, A4 and Lii, or combination of two amino acids A4, and Lii is a combination corresponding to a target RNA base or base sequence.

公开(公告)号：US20230243830A1

公开(公告)日：2023-08-03

申请号：US18163149

申请日：2023-02-01

Applicant: Freenome Holdings, Inc.

Inventor： Brian D. O'DONOVAN ,  Shivani MAHAJAN

IPC: G01N33/574 ,  G01N33/68 ,  G16B35/00

CPC classification number: G01N33/57419 ,  G01N33/6854 ,  G16B35/00

Abstract: Systems, media, compositions, methods, and kits disclosed herein relate to a panel of autoantibody biomarkers for the early detection of colon cell proliferative disorders, including colorectal cancer. The presence or levels of the autoantibodies in a biological sample for the autoantibody panels described herein may be used for classifier generation, and as inputs in machine learning models useful to classify subjects in a population for the detection of colon cell proliferative disorders.

公开(公告)号：US20230212558A1

公开(公告)日：2023-07-06

申请号：US17570073

申请日：2022-01-06

Applicant: Palo Alto Research Center Incorporated

Inventor： Jerome UNIDAD ,  Sean DORIS

IPC: C12N15/10 ,  C12N15/115 ,  G16B35/00 ,  G01N15/10

CPC classification number: C12N15/1089 ,  C12N15/115 ,  G16B35/00 ,  G01N15/1056 ,  C12N2310/16 ,  C12N2320/13 ,  G01N2015/1006

Abstract: Molecular beacons and developmental methods related thereto. Methods include obtaining a nucleotide sequence for an aptamer that binds to a target analyte. The aptamer comprises a binding domain nucleotide sequence, a first domain nucleotide sequence, and a displacement domain nucleotide sequence complementary to the first domain nucleotide sequence. A molecular beacon is developed based on the nucleotide sequence of the aptamer by preserving the binding domain nucleotide sequence and truncating or extending one or both of the first domain nucleotide sequence or the displacement domain nucleotide sequence. The resultant molecular beacon is developed such that the molecular beacon comprises a Gibbs free energy value that is greater than the Gibbs free energy value of the aptamer.

公开(公告)号：US20230197187A1

公开(公告)日：2023-06-22

申请号：US17933028

申请日：2022-09-16

Applicant: BIONIZ, LLC

Inventor： Nazli Azimi ,  Yutaka Tagaya

IPC: G16B15/00 ,  G16B20/00 ,  G16B35/00 ,  G16C20/60 ,  G16B35/20 ,  G16B20/50 ,  G16B20/30 ,  G01N33/50

CPC classification number: G16B15/00 ,  G16B20/00 ,  G16B35/00 ,  G16C20/60 ,  G16B35/20 ,  G16B20/50 ,  G16B20/30 ,  G01N33/5041 ,  G16B15/30

Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.